13F filer · CIK 1263048
MPM ASSET MANAGEMENT LLC
BOSTON, MA · filing since Q2 2013 · last filing Nov 14, 2025
Reported value
$44.5M
+$1.2M vs prior
Positions
4
New / sold out
0 / 1
Added / reduced
0 / 0
Turnover
0.0%
buys $0 · sells $1.2M
Top-10 weight
100.0%
Biggest buys vs Q2 2025
No new or increased positions this quarter.
Biggest sells vs Q2 2025
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | Adaptimmune Therapeutics plc | -4,809,677 | -100.0% | $-1.2M |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q3 2025
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Entrada Therapeutics, Inc.COMMON | 4,381,062 | $25.4M | 57.09% |
| 2 | Dyne Therapeutics, Inc.COMMON | 682,376 | $8.6M | 19.40% |
| 3 | Werewolf Therapeutics, Inc.COMMON | 4,309,860 | $8.5M | 19.08% |
| 4 | Repare Therapeutics, Inc.COMMON | 1,121,318 | $2.0M | 4.43% |